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Hyperglycemia promotes oxidative stress and hence generation of reactive oxygen species (ROS), which is known to play a crucial
role in the pathogenesis of diabetic nephropathy. Metformin, an oral hypoglycemic drug, possesses antioxidant eﬀects. The aim
of this paper is to investigate the protective eﬀects of metformin on the injury of renal podocytes in spontaneously diabetic Torii
(SDT) rats, a new model for nonobese type 2 diabetes. Metformin (350mg/kg/day) was given to SDT rats for 17 weeks. Blood
glucose,glycatedhaemoglobin(HbA1c),andalbuminuriawereexamined.Kidneyhistopathology,renal8-hydroxydeoxyguanosine
(8-OHdG) levels and apoptosis were examined. In 43-week-old SDT rats, severe hyperglycemia was developed, and albuminuria
was markedly increased. Diabetes induced signiﬁcant alterations in renal glomerular structure. In addition, urinary and renal 8-
OHdG levels were highly increased, and podocyte loss was shown through application of the TUNEL and synaptopodin staining.
However, treatment of SDT rats with metformin restored all these renal changes. Our data suggested that diabetes-induced
podocyte loss in diabetic nephropathy could be suppressed by the antidiabetes drug, metformin, through the repression of
oxidative injury.
1.Introduction
Diabetic nephropathy is one of the most serious complica-
tionsofbothtype1andtype2diabetismellitus[1].Theclin-
ical hallmarks of diabetic nephropathy include progressive
albuminuria followed by a gradual decline in renal function
[2]. The loss of glomerular podocytes precedes and predicts
the onset of clinical nephropathy and may be an early patho-
logical manifestation of diabetic nephropathy [3, 4]. Among
the three intrinsic cells in glomerulus, podocyte is one of
the important ingredients of ﬁltration barrier which has
special cytobiological trait and physiological function. The
injury of podocyte can inevitablely lead to the occurrence of
proteinuria[5].Patientswithadvanceddiabeticnephropathy
have few treatment options and often have a poor prognosis
[6].
Metformin has been widely used for treating type 2
diabetes without the stimulation of insulin production [7].
In previous study, metformin could reduce macrovascular
morbidity and mortality, suggesting that it achieved its
antiatherogenic, anti-inﬂammatory, and antioxidant eﬀects
[8,9].Moreover,metforminsigniﬁcantlydecreasedtheurine
albumin excretion rate in patients with type 2 diabetes
[10]. The beneﬁts of metformin with regard to the risk of
cardiovascular outcomes and metabolic parameters suggest
its clinical use in treating chronic kidney disease [11]. The
precise mechanisms beyond the eﬀect of metformin on glu-
cose still are obscure. Recent studies suggest that therapeutic
eﬀect of metformin might be mediated by its action on
AMP-activated kinase (AMPK) in peripheral tissues [12, 13].
Other studies show that metformin decreases intracellular
ROS [14, 15].
Diabetic animal models have a critical role in the elu-
cidation of the mechanisms of diabetic complications and
the development of novel drugs as treatments. The sponta-
neously diabetic Torii (SDT) rat is a new model for nonobese
type 2 diabetes that spontaneously develops hyperglycemia
and glucose intolerance resulting from decreased insulin
secretion accompanying β-cell degeneration [16]. SDT rat is
an ideal model for investigating diabetic complications with2 Experimental Diabetes Research
gradual progression and is the only diabetic model known
with progression to proliferative retinopathy [17, 18].
In the present study, we examined the utility of the SDT
rat as a model of diabetic nephropathy, and investigated
the preventive eﬀect of metformin on the injury of diabetic
glomerular podocytes in SDT rats.
2.MaterialsandMethods
2.1.Animals. Theexperimentswereperformedaccordingto
the National Institutes of Health (NIH) Guide for the Care
and Use of Laboratory Animals and approved by the Korea
Institute of Oriental Medicine Institutional Animal Care and
Use Committee. Male SDT rats and age-matched Sprague-
Dawley (SD) rats were purchased from CLEA Japan (Tokyo,
Japan)andacclimatedfor1weekpriortothestudy.Ratswere
individually housed in plastic cages and maintained at 24◦C
± 2◦C with a 12h light:dark cycle and received a basal diet
(ground Purina rat chow, Ralston Purina, MO, USA) and
tap water ad libitum. At 25 weeks of age, the animals were
randomly divided into three groups as follows: (1) normal
SD rats (NOR, n = 10), (2) vehicle-treated SDT rats (SDT,
n = 10), and (3) SDT rats treated with metformin (SDT +
MET, 350mg/kg body weight). Metformin was administered
once a day orally for 17 weeks. The blood glucose level
and body weight were monitored consecutively, and glycated
hemoglobin was determined by a commercial kit (Unimate
HbA1c, Roche Diagnostics, Mannheim, Germany).
2.2. Metabolic and Morphological Analysis. When the rats
reached 43 weeks of age, blood glucose and HbA1c (A1C)
were measured using an automated analyzer (Wako, Japan).
Blood samples were collected from the tail vein after a 16h
fast. Individual rats were placed in metabolic cages to obtain
24h urine collections, and daily urinary albumin excretion
levels were measured. Renal cortexes were ﬁxed in 10%
formaldehyde and embedded in paraﬃn, and 4μm thick sec-
tions were prepared. The sections were stained with periodic
acid-Schiﬀ (PAS) reagent or Masson’s modiﬁed trichrome
to assess glomerulosclerosis and demonstrate collagenous
tubulointerstitial matrix, respectively.
2.3. Measurement of Urinary 8-Hydroydeoyguanosine (8-
OhdG). 24h urine samples were collected from rats. The
samples were purged of air with a steam of nitrogen to pre-
vent the artiﬁcial formation of 8-OHdG and stored frozen
at −80◦C until analyzed. Urine samples were centrifuged at
2,000g for 20min, and after proper dilution, the supernatant
was used for the determination of 8-OHdG by a competitive
enzyme-linked immunosorbent assay (ELISA) kit (Japan
Institute for the Control of Aging, Fukuroi, Japan). The
urinary 8-OHdG was expressed as total amounts excreted in
24h.
2.4. Measurement of 8-OHdG Levels in Renal Tissues. The
kidney was rapidly excised. The renal cortex tissues were
homogenized in 5mL of 50mmol/L Tris-HCl (pH 7.4).
The homogenates were centrifuged at 800g for 10min to
precipitate nuclear fraction, and 1mL of solution con-
taining 10mmol/L EDTA, 10mmol/L Tris-HCl (pH 8.0),
150mmol/L NaCl, and 0.2% SDS was added. After homog-
enization, the mixture was incubated at 56◦Cf o r7 0 m i n
with proteinase K (700μg/mL) and then heated at 95◦Cf o r
10min. DNA was extracted with equal volumes of phenol,
chloroform, and isoamyl alcohol (25:24:1) and then with
chloroform. DNA was precipitated with 70% ethanol at
−20◦C for 2h. DNA was resuspended in 10mmol/L Tris-
HCl and 0.1mmol/L EDTA (pH 8.0). Five microliters
of 200mmol/L sodium acetate buﬀer (pH 4.8) and 5μg
nucleaseP1(Invitrogen,CA,USA)wereaddedto45μLDN A
samples. The mixtures were incubated at 37◦Cf o r1 ht o
digest the DNA to nucleotides. Then, 5μL of 500mmol/L
Tris-HCl (pH 8.0), 10mmol/L MgCl2, and 0.6 units alkaline
phosphatase (Toyobo, Osaka, Japan) were added to the sam-
ples. The mixtures were incubated at 37◦Cf o r1 ht o
hydrolyze the nucleotides to nucleosides. The nucleoside
samples were used for the determination of 8-OHdG by
competitive ELISA kit as described above.
2.5. Double Labelling for TUNEL and Synaptopodin Expres-
sion. TUNEL was performed with the In-situ cell death
detection kit AP (Roche Diagnostics, Mannheim, Germany)
according to the manufacturer’s instructions. Apoptotic cells
were detected with a colour solution containing nitrob-
lue tetrazolium (NBT, Roche Diagnostics) and 5-bromo-
4-chloro-3-indolylphosphate (BCIP, Roche Diagnostics).
Labelling with mouse anti-synaptopodin antibody (Santa
Cruz Biotechnology, CA, USA) was performed subsequently
on the same sections with secondary detection by horserad-
ish peroxidase-conjugated anti-mouse IgG antibody (Santa
Cruz) and an AEC Red peroxidase substrate kit (Vector
Laboratories, Burlingame, California). To prevent cross-
reaction between the two labelling procedures the slides
were incubated with normal mouse serum (Dako) after the
TUNEL labelling. For morphometric analysis, the areas of
positive signal for synaptopodin per glomerulus over a total
of 40 glomeruli was determined using Image J software,
and cells dually labelled for TUNEL and synaptopodin were
counted.
2.6. Immunohistochemical Staining for WT-1. Staining was
performed as previously described [19]. Antibody was rabbit
anti-Wilms tumor antigen-1 (WT-1, 1:250, Santa Cruz).
The sections were visualized by nitroblue tetrazolium
chloride (NBT) and 5-bromo-4-chloro-3-indolyl phosphate
(BCIP) substrate staining and counterstained with methyl
green. Negative controls for immunohistochemistry were
run by incubating the sections with nonimmune serum
instead of the primary antibody. For morphometric analysis,
the positive cell numbers per glomerulus in a total of 40
glomerulus was determined.
2.7. Western Blotting Analysis in Retinal Tissues. Proteins
were extracted from renal tissues, and then 20μgo fp r o -
tein lysates was separated by SDS-polyacrylamide gel elec-
trophoresis and transferred to nitrocellulose membranes
(Biorad, CA, USA). Membrane was probed with mouseExperimental Diabetes Research 3
Table 1: Metabolic and physical parameters.
NOR SDT MET
Body weight (g) 713.9 ±29.7 375.5 ±52.4
∗ 430.5 ±13.4
Blood glucose (mg/dL) 144.1 ±21.0 419.2 ±21.2
∗ 359.5 ±52.3
HbA1c (%) 3.49 ±0.07 9.13 ±0.37
∗ 7.82 ±0.29
NOR: normal rat; SDT: spontaneously diabetic Torii rat; MET: SDT rat
treated with metformin (350mg/kg/day). All data are expressed as mean ±
SE (n = 8). ∗P<0.01 versus NOR group. #P<0.01 versus SDT group.
anti-AMPK antibody (Santa Cruz) and mouse anti-phos-
pho-AMPK antibody (Santa Cruz), and then the immune
complexes were visualized with an enhanced chemilumines-
cence detection system (Amersham Bioscience, NJ, USA).
2.8. Statistical Analysis. Data are expressed as mean±SE and
analyzed by one-way analysis of variance (ANOVA) followed
byTukey’smultiplecomparisontestorbyunpairedStudent’s
t-test using GraphPad Prism 5.0 software (Graph pad, San
Diego, CA, USA). Diﬀerences with a value of P<0.01 were
considered statistically signiﬁcant.
3. Results
3.1. Body Weight and Metabolic Parameters in Blood. In SDT
diabetic rats at 43 weeks of age, body weight was decreased
compared with normal rats and did not change compared
with rats that treated metformin. Blood glucose and HbA1c
levels were signiﬁcantly increased in SDT rats (P<0.01
versus normal rats). Metformin induced a minor decrease of
blood glucose and HbA1c levels (Table 1).
3.2. Morphology and Renal Function. Mesangial matrix
expansion is considered a hallmark of diabetic nephropathy.
At 43 weeks of age, SDT rats showed focal mesangial matrix
expansion, tubulointerstitial damage, and albuminuria were
signiﬁcantly increased in SDT rats compared to normal rats.
Metformin treatment ameliorated mesangial expansion and
albuminuria, compared with untreated SDT rats (Figures
1(a) to 1(c)).
3.3. Quantiﬁcation of 8-OHdG in Urine and Renal Tissue.
The total amounts of urinary 8-OHdG excretion were
signiﬁcantly greater in SDT rats than in normal rats (Fig-
ure 2(a)). The levels of 8-OHdG in renal cortex tissues
were signiﬁcantly increased in SDT rats as compared with
those from the normal rats (Figure 2(b)). Similarly, There
was increased expression of 8-OHdG in the podocytes of
SDT rats and this labelling had a nuclear and/or perinuclear
localization(Figure2(c)).Metforminreducedthesediabetes-
induced increases in urinary and renal 8-OHdG.
3.4. Apoptosis of Renal Podocytes in SDT Rats. In SDT rats,
many podocytes, mesangial cells, and capillary endothelial
cells were positively labelled by the TUNEL technique.
However, metformin prevented the increase in the positive
cells that was seen in normal kidney. Average numbers of
podocytesperglomerularsectionweredeterminedbycount-
ing cells and measuring areas that were positively labeled
with two podocyte markers, such as synaptopodin and WT-
1 In SDT rats, synaptopodin and WT-1-positive cell counts
tended to decrease compared with age-matched normal rats.
Treatment with metformin visibly increased the positive cells
and areas in the kidney glomeruli (Figures 3(a) to 3(d)). In
dual-labelled sections, TUNEL-positive cells were localized
to the regions of synaptopodin expression consistent with
apoptosis of podocytes in diabetic renal tissue (Figures 3(a)
and 3(e)).
3.5. Changes in AMPK Activation in SDT Rats. We assessed
whether metformin activates AMPK in the kidney using
immunoblotting for phosphorylation of AMPK. Activation
of AMPK was signiﬁcantly reduced in the kidney of SDT rats
compared with normal rats, and metformin induced AMPK
activation in the kidney (Figures 4(a) and 4(b)).
4. Discussion
Animal models traditionally employed in the investigation
of diabetic nephropathy include STZ-induced diabetic rats,
but the general pathophysiology of disease in these models
diﬀers from that of NIDDM in man. The SDT rat, a model
of nonobese type 2 diabetes, was established in 1997 by Shi-
nohara et al. [18]. Hyperglycemia spontaneously develops in
SDT rats, predominantly due to an insulin secretary defect.
In addition to marked hyperglycemia, renal complications
are a characteristic of SDT rats [20]. Based on the ﬁndings of
the present study, SDT rat may be an appropriate an animal
model for investigation of diabetic nephropathy. This model
has many similarities to human NIDDM and the develop-
ment of diabetes mellitus in SDT rats is accompanied by
functional and morphological kidney damage that resembles
human diabetic nephropathy [20, 21].
Growing evidence suggests that the overproduction of
ROS may be the key initiating event that leads to the long-
term development of diabetic complications [22]. However,
the speciﬁc mechanisms that link hyperglycemia with oxida-
tive stress and diabetic nephropathy are poorly understood.
In general, oxidative stress can aﬀect nucleic acids and
generate various modiﬁed bases in DNA. 8-OHdG is the
most abundant and appears to play a crucial role in
mutagenesis [23]. Oxidation of guanine to form 8-OHdG
acts as a marker of oxidative DNA damage [24]. When DNA
isdamaged,cellsinitiatearesponse,suchasDNArepair,cell-
cycle delay, or induction of apoptosis [25]. Increased levels
of 8-OHdG have been reported in urine [26], mononuclear
cells [27] and skeletal muscles [28] of diabetic patients. The
levels of 8-OHdG were increased in kidney tissues of STZ-
induced diabetic rats [29]. In the present study, we further
revealedthatlevelsof8-OHdGwereincreasedinrenaltissues
of SDT rats. To localize expression of 8-OHdG in diabetic
kidneys, kidney tissues were analyzed by imunohistochem-
ical staining. Although the method for 8-OHdG detection
stainsnuclearDNAaswellasmitochondrialDNA(mtDNA),
thestainingwaslocalizedmainlyinthecytoplasm,indicating
that this oxidative adduct was present in mtDNA, but not in
nuclear DNA. It is accepted that vulnerability to oxidative
damage and subsequent mutations is 10–20 times greater4 Experimental Diabetes Research
NOR SDT MET
(a)
(b)
17.5
15
12.5
10
7.5
5
2.5
0
NOR SDT MET
A
l
b
u
m
i
n
u
r
i
a
 
(
m
g
/
d
a
y
)
∗
#
(c)
Figure 1: Renal histopathology and function(a). Periodic acid-Schiﬀ staining of glomeruli, ×400 magniﬁcation (b). Masson’s trichrome
stained renal sections, ×400 magniﬁcation (c). Albuminuria in normal rat (NOR), spontaneously diabetic Torii rat (SDT) and SDT rat
treated with 350mg/kg metformin (MET). All data are expressed as mean ± SE (n = 8). ∗P<0.01 versus NOR group, #P<0.01 versus SDT
group.
for mtDNA than for nuclear DNA [30, 31]. In parallel with
the results of renal tissues, the amounts of urinary 8-OHdG
excretion were markedly increased in SDT rats. Although
urinary 8-OHdG levels are supposed to be markers of the
total systemic oxidative stress in vivo [32], the relative
contribution of renal 8-OHdG to urinary 8-OHdG should
be evaluated in future studies.
The generation of ROS through oxidative stress causes
cell death [33]. Apoptosis, which is characterized by chro-
matin condensation, DNA fragmentation, and the activation
of caspases, has been implicated in the pathogenesis of
various renal diseases, including diabetic nephropathy [34,
35]. ROS are potent inducers of apoptosis in various cell
types including murine and human podocytes [36–38]. OurExperimental Diabetes Research 5
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Figure 2: Expression of 8-OHdG in urine and renal tissues. (a) Uriany 8-OHdG excretion levels, (b) renal 8-OHdG levels, and (c)
immunohistochemicalstatingfor8-OHdGinnormalrat(NOR),spontaneouslydiabeticToriirat(SDT)andSDTrattreatedwith350mg/kg
metformin (MET). All data are expressed as mean ±SE (n = 8). ∗P<0.01 versus NOR group, #P<0.01, versus SDT group.
present study shows that the density of podocytes decreases
in SDT rats in association with increased albuminuria.
Podocyte apoptosis has been demonstrated to correlate with
worsening albuminuria [38]. Furthermore, strong evidence
hasestablishedaroleforintracellularROSaspotentinducers
of podocyte apoptosis [39]. The increase in antioxidant
enzymes such as heme oxygenase-1 has been shown to
reduce podocyte apoptosis under diabetic conditions [40].
Consistent with this interpretation, the results of the present
studydemonstratethattheincreased8-OHdGconcentration
in aﬀected renal glomeruli is involved, at least in part, in the
injury of podocytes.
In addition, we examined the eﬀect of intervention by
metformin treatment on the increases in 8-OHdG levels and
podocyte loss in kidney tissues of diabetes. It is of great
interest that intervention by metformin treatment inhibited
both increases in renal 8-OHdG levels and podocyte loss in
kidney of SDT rats. The treatment of SDT rats with met-
formin slightly decreased blood glucose and HbA1c levels.
Hyperglycemia, a key clinical manifestation of diabetes, is
supposed to generate ROS through various mechanisms,
such as increased formation of advanced glycation end prod-
ucts (AGEs) [41], enhanced polyol pathway [42], increased
superoxide release from mitochondria [43], and activation
of NAD(P)H oxidase [44]. In our present study, metformin
induced only a minor decrease of levels of blood glucose
(22%) and HbA1c (23%) in SDT rats. Similarly, metformin
failed to reduce blood glucose levels in ZDF rats [45].
Although metformin has a weak glucose-lowering eﬀect in
SDT rats, metformin has signiﬁcant eﬀects on any param-
eters of renal structure and function without the strong
reduction of blood glucose. The level of albuminuria was
decreased by 63% in metformin-treated SDT rats. However,
Fujii H et al. showed that the treatment of insulin decreased
the level of HbA1c by almost 55% [46]. The level of
albuminuria was also decreased by 62% in insulin-treated
SDT rats. These ﬁndings suggest that even in hyperglycemia,
it is possible to attenuate podocyte injury by metformin.6 Experimental Diabetes Research
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Figure 3: Podocyte loss. A representative photomicrograph of (a) dual labelling for TUNEL (black) and synaptopodin (red) and (b) WT-
1( b l a c k ) .×400 magniﬁcation. Double-positive cells (magniﬁed inset) indicates the colocalization of the podocyte marker and apoptosis.
Quantitative analyses of (c) positive areas of synaptopodin, (d) positive cells of WT-1 and (e) TUNEL and synaptopodin-double-positive
cells. All data are expressed as mean ±SE (n = 8). ∗P<0.01 versus NOR group, #P<0.01, versus SDT group.
Metformin has been found to activate AMPK, a major
cellular regulator of lipid and glucose metabolism [13]. Pre-
vious studies also have shown that metformin is an inhibitor
ofcomplexIofthemitochondrialrespiratorychainindepen-
dent of the AMPK pathway [47, 48] and a potent inhibitor
of AGE formation [49]. AMPK pathway acts as a signal
for ATP generation, a process coupled to increase in ROS
production. AMPK pathway can be activated by intracellular
ROS and reduces ROS levels [50, 51]. The ability of AMPK
to simultaneously reduce ROS levels and counterbalance
the overproduction of ROS is an important mechanism for
controlling the redox balance during energy production. In
present study, we found that the phosphorylation of AMPK
was reduced in the kidney of SDT rats, and metformin could
restore its alteration. Therefore, metformin is likely exerting
some of its eﬀects via improvement of renal oxidative stress.
It could be reasonable to assume that the renoprotective
eﬀect of metformin might be at least partly, attributed to itsExperimental Diabetes Research 7
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Figure 4: AMPK activation in renal tissues. (a) Representative
immunoblots of phospho-AMPK and AMPK in protein extracts
from the kidneys of rats of each group. (b) Quantitative analysis
of protein expression. All data are expressed as mean ± SE (n = 8).
∗P<0.01 versus NOR group, #P<0.01, versus SDT group.
inﬂuence on AGEs formation and ROS production, besides
its antihyperglycemic eﬀect. These observations suggest a
potential clinical use of metformin in the prevention of
diabetic nephropathy by inhibition of AGEs and improving
the free-radical defense system. Liu et al. have pointed the
beneﬁcial antioxidant eﬀects of metformin in STZ-induced
DM in rats [52].
In conclusion, SDT rat is a useful model for the evalua-
tion of the eﬀects of drugs and the investigation of diabetic
nephropathy. We also demonstrated that metformin protects
against diabetic nephropathy by restoring the biochemical
alterations and modulation of oxidative stress, and hence
suggests a potential clinical use of metformin in the preven-
tion of diabetic nephropathy.
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